Gemcitabine and Nexavar drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Gemcitabine (gemcitabine) and Nexavar (sorafenib tosylate). Common drug interactions include abdominal pain upper among females and dyspnoea among males.

The phase IV clinical study analyzes what interactions people have when they take Gemcitabine and Nexavar. It is created by eHealthMe based on reports of 24 people who take the same drugs from the FDA, and is updated regularly.

What is Gemcitabine?

Gemcitabine has active ingredients of gemcitabine. eHealthMe is studying from 31,337 Gemcitabine users. Check the latest studies of Gemcitabine.

What is Nexavar?

Nexavar has active ingredients of sorafenib tosylate. It is often used in hepatocellular carcinoma. eHealthMe is studying from 23,250 Nexavar users. Check the latest studies of Nexavar.

On Jul, 15, 2026

24 people who take Gemcitabine and Nexavar together, and have interactions are studied.

Gemcitabine and Nexavar drug interactions.

What are the common drug interactions of Gemcitabine and Nexavar, by gender? *:

female:

Abdominal pain upper
Fatigue (feeling of tiredness)
Hypertension (high blood pressure)
Cardiac failure
Dyspnoea (difficult or laboured respiration)
Pleural effusion (water on the lungs)
Urinary tract obstruction

male:

Dyspnoea (difficult or laboured respiration)
Diarrhoea
Skin disorder (skin disease)
Skin fibrosis (fibrous tissue formation on skin)
Blood bilirubin increased
Arteriospasm coronary (spasm of the large- or medium-sized coronary arteries)
Ejection fraction decreased (systolic heart failure)
Hepatic neoplasm malignant (liver cancer)
Hypotension (abnormally low blood pressure)
Multi-organ failure (multisystem organ failure)

What are the common drug interactions of Gemcitabine and Nexavar, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Drug ineffective
Hepatoblastoma (liver cancer)
Malignant neoplasm progression (cancer tumour came back)
Terminal state (the transitional states between life and biological death)

10-19:

Urinary tract obstruction

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Anxiety
Arteriospasm coronary (spasm of the large- or medium-sized coronary arteries)
Arthropathy
Cardiac disorder
Dyspnoea (difficult or laboured respiration)
Ejection fraction decreased (systolic heart failure)
Hepatic neoplasm malignant (liver cancer)
Hypotension (abnormally low blood pressure)
Mobility decreased (ability to move is reduced)
Multi-organ failure (multisystem organ failure)

60+:

Diarrhoea
Fatigue (feeling of tiredness)
Dysphonia (speech disorder attributable to a disorder of phonation)
Hospitalisation
Hypersomnia (excessive daytime sleepiness (eds))
Hypertension (high blood pressure)
Impaired work ability
Jaundice (a yellowish pigmentation of the skin, the conjunctival membranes)
Palmar-plantar erythrodysaesthesia syndrome (hand-foot syndrome)
Pyrexia (fever)

What are the existing conditions these people have? *

Pain: 5 people, 20.83%
High Blood Pressure: 5 people, 20.83%
Hepatic Neoplasm Malignant (liver cancer): 5 people, 20.83%
Tumor: 4 people, 16.67%
Stress And Anxiety: 4 people, 16.67%
Pancreatic Carcinoma (pancreatic cancer): 4 people, 16.67%
Neoplasm Malignant (cancer tumour): 4 people, 16.67%
Constipation: 4 people, 16.67%
Type 2 Diabetes: 3 people, 12.50%
Renal Cell Carcinoma Stage Unspecified (kidney cancer in unknown stage): 2 people, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Gemcitabine and Nexavar?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously